

"What I didn't fully appreciate at the time was why XEIOH held up: the formalised governance systems had been imposed on us by pharmaceutical client and vendor requirements. I hadn't designed them for resilience — I'd built them to keep clients. The resilience was a benefit I only recognised in hindsight."
"Structure isn't innovation's enemy. It's the multiplier that makes innovation defensible when clients test it."

